Compare ESAB & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESAB | IRTC |
|---|---|---|
| Founded | 1904 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 4.8B |
| IPO Year | 2022 | 2016 |
| Metric | ESAB | IRTC |
|---|---|---|
| Price | $108.16 | $119.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $144.13 | ★ $209.69 |
| AVG Volume (30 Days) | 357.8K | ★ 619.9K |
| Earning Date | 05-25-2026 | 05-25-2026 |
| Dividend Yield | ★ 0.37% | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 3.67 | N/A |
| Revenue | ★ $2,842,555,000.00 | $747,138,000.00 |
| Revenue This Year | $6.42 | $19.58 |
| Revenue Next Year | $5.59 | $15.95 |
| P/E Ratio | $29.43 | ★ N/A |
| Revenue Growth | 3.71 | ★ 26.24 |
| 52 Week Low | $100.17 | $92.52 |
| 52 Week High | $137.42 | $210.01 |
| Indicator | ESAB | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 29.44 |
| Support Level | N/A | $119.48 |
| Resistance Level | $118.33 | $167.19 |
| Average True Range (ATR) | 4.28 | 6.99 |
| MACD | -2.41 | -1.04 |
| Stochastic Oscillator | 12.61 | 2.67 |
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.